(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
10 Moves toward Start Your Own Effective Business- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- Most loved Fish Dish: What's Your Sea Pleasure?
- Vote In favor of Your Number one Game Control center
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- Supportive Tips On Home loans For First-Time Home Purchasers
- Believe Should Unwind? Look at These Scaled down Games
